PUMA BIOTECHNOLOGY, INC. (PBYI) Stock Profile — Insider Trades & Financials

Smart-Money SignalNeutral · 51/100— Insiders are net sellers over 90 days (-$612K, 2 sales vs 0 buys)

Revenue$56.5M

Net Income$8.2M

EPS$0.08

Market Cap$517.2M

Price Performance

Historical data including institutional events

Company Profile

Alan Auerbach

CEO & Executive Director

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Founded: 2010
Employees: 265
Headquarters: LOS ANGELES, CA, United States
Website: www.pumabiotechnology.com

Peer ComparisonRevenue ($B)

▾

Loading company sections...

Smart-Money SignalNeutral · 51/100— Insiders are net sellers over 90 days (-$612K, 2 sales vs 0 buys)

Revenue$56.5M

Net Income$8.2M

EPS$0.08

Market Cap$517.2M

Price Performance

Historical data including institutional events

Company Profile

Alan Auerbach

CEO & Executive Director

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Founded: 2010
Employees: 265
Headquarters: LOS ANGELES, CA, United States
Website: www.pumabiotechnology.com

Peer ComparisonRevenue ($B)

▾

Smart-Money Signal

90-DAY POSTURE

51/ 100

NEUTRAL

Insiders are net sellers over 90 days (-$612K, 2 sales vs 0 buys). Smart-money posture is balanced.

Insider flow · 90d-$612K

Congress flow · 90dno activity

10b5-1 share100% planned

Cluster selling2 officers

Price vs 52w98% of high

Cross-Section Event Timeline

INSIDERS · CONGRESS · EARNINGS

INSIDER GRANT / AWARDAlessandra Cesano (Director) GRANT / AWARD PBYIJun 11, 2026

INSIDER GRANT / AWARDAllison Dorval (Director) GRANT / AWARD PBYIJun 11, 2026

INSIDER GRANT / AWARDJay M. Moyes (Director) GRANT / AWARD PBYIJun 11, 2026

INSIDER GRANT / AWARDMichael Patrick Miller (Director) GRANT / AWARD PBYIJun 11, 2026

INSIDER SELLAllison Dorval (Director) SELL PBYIJun 12, 2026

INSIDER SELLJay M. Moyes (Director) SELL PBYIJun 12, 2026

INSIDER SELLAdrian Senderowicz (Director) SELL PBYIJun 12, 2026

INSIDER SELLBrian M. Stuglik (Director) SELL PBYIJun 12, 2026

INSIDER SELLTroy Edward Wilson (Director) SELL PBYIJun 12, 2026

INSIDER SELLMaximo F. Nougues (Chief Financial Officer) SELL PBYIJul 6, 2026

INSIDER SELLDouglas M. Hunt (See Remarks) SELL PBYIJul 6, 2026

INSIDER SELLAlan H. Auerbach (President and CEO) SELL PBYIJul 6, 2026

INSIDER SELLAlessandra Cesano (Director) SELL PBYISep 14, 2026

INSIDER EXERCISE / CONVERSIONAlessandra Cesano (Director) EXERCISE / CONVERSION PBYISep 14, 2026

INSIDER SELLTroy Edward Wilson (Director) SELL PBYISep 14, 2026

⚡

Core Efficiency

ROE?

5.91%

ROA?

4.25%

D/E Ratio?

0.39

Op. Margin?

13.42%

📊

Profitability Ratios

Net Margin?

14.49%

Current Ratio?

2.91

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Nov 10, 2026 (in 27 days)

Quarterly Report (10-Q) — Based on filing pattern

Nov 10, 2026

Predicted10-Q

Aug 6, 2026

10-QQ2 202637d after period end

May 7, 2026

10-QQ1 202637d after period end

Feb 26, 2026

10-KQ4 202557d after period end

Feb 26, 2026

10-KFY 202557d after period end

Nov 6, 2025

10-QQ3 202537d after period end

Aug 7, 2025

10-QQ2 202538d after period end

Feb 27, 2025

10-KFY 202558d after period end

Data Freshness

Financial Data

2mo ago

SEC Metadata

2mo ago

Latest filing: 2026-08-06

Loading company sections...

PUMA BIOTECHNOLOGY, INC.

Price Performance

Company Profile

PUMA BIOTECHNOLOGY, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

PUMA BIOTECHNOLOGY, INC.

Price Performance

Company Profile

The morning brief, before the bell.

PUMA BIOTECHNOLOGY, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades